Due to high expression of IL-2Rβγ in tumor-infiltrated CD8+ T and NK cells, delivery of an IL-2Rβγ agonist to these cells might enhance the intratumoral antitumor immune responses. This evidence concerns the gene CD8A and neoplasm.